SCHEMBL2861196

SCHEMBL2861196

COc1ccc(Cn2c(=O)c3c(N)n(-c4ccc(Oc5ccccc5)cc4)nc3c3cc(OC)c(OC(C)C)cc32)cc1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.42
MEN1 O00255 1/20 0.42
GAA P10253 1/20 0.42
MAPT P10636 1/20 0.42
KMT2A Q03164 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.39
THRB P10828 1/20 0.39
KDM4E B2RXH2 1/20 0.38
TP53 P04637 2/20 0.37
RXFP1 Q9HBX9 2/20 0.37
NPBWR1 P48145 1/20 0.37
TSHR P16473 1/20 0.36
ADORA3 P0DMS8 1/20 0.36
BLM P54132 1/20 0.36
EDNRB P24530 1/20 0.36
EDNRA P25101 1/20 0.36
P2RX4 Q99571 1/20 0.36
PIK3CD O00329 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2865409 0.95 KDM4E (0.41) MAPTKMT2ASMN1; SMN2KDM4ETP53
SCHEMBL2867619 0.90 BCL2 (0.40) MAPK1MEN1GAAMAPTKMT2A
SCHEMBL2856173 0.88 MEN1 (0.41) MAPK1MEN1GAAMAPTKMT2A
SCHEMBL2868756 0.87 KMT2A (0.48) MAPK1MEN1MAPTKMT2ASMN1; SMN2
SCHEMBL2863040 0.86 MAPT (0.43) MAPK1MEN1GAAMAPTKMT2A
SCHEMBL2862341 0.84 PDE1B (0.40) MAPK1GAAMAPTTP53RXFP1
SCHEMBL2871290 0.84 MAPT (0.42) MAPK1MEN1GAAMAPTKMT2A
SCHEMBL2866734 0.84 MAPT (0.42) MAPK1MEN1GAAMAPTKMT2A
SCHEMBL2865359 0.83 ADORA3 (0.39) MAPK1GAAMAPTSMN1; SMN2THRB
SCHEMBL2860751 0.83 P2RX4 (0.44) MEN1GAAMAPTKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
EP-1719771-A1 PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof MAP3K20, MAP4K5, MAP4K3 MAPK1 58/4885MEN1 3903/4885GAA 4868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.